Onkologie. 2024:18(4):275-278 | DOI: 10.36290/xon.2024.057
Cemiplimab in the treatment of locoregionally metastasizing cutaneous squamous cell carcinoma
- Dermatovenerologická klinika, 1. LF UK a VFN, Praha
The presented case report describes the case of a patient with repeatedly recurring locoregionally metastasizing squamous cell skin carcinoma of the left auricle, who was treated with cemiplimab immunotherapy after exhausting the possibilities of surgical treatment and actinotherapy. After completing 10 doses, complete remission was achieved, and therapy was discontinued at the patient's request. Complete clinical and radiological remission of the disease lasts 3 months after stopping treatment.
Keywords: locoregionally metastasizing cutaneous squamous cell carcinoma, disease recurrence, actinotherapy, cemiplimab.
Accepted: October 1, 2024; Published: October 7, 2024 Show citation
References
- Stratigos AJ, Garbe C, Dessinioti C, et al. European Dermatology Forum (EDF), the European Association of Dermato‑Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. Epidemiology, diagnostics and prevention. Eur J Cancer. 2020;128:60-82.
Go to original source... 
Go to PubMed... - Důra M. Cemiplimab. Remedia. 2021;31:455-460. Go to original source...
- Stratigos AJ, Garbe C, Dessinioti C, et al. European Dermatology Forum (EDF), the European Association of Dermato‑Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur J Cancer. 2020;128:83-102. Go to original source... Go to PubMed...
- SPC Libtayo. Available from: Libtayo, INN-cemiplimab (europa.eu) Libtayo, INN-cemiplimab (europa.eu).
- Migden MR, Schmults C, Khushanlani N, et al. Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Ann Oncol. 2022;33 (suppl_7):S356-S409. Go to original source...
- Lorini L, Alberti A, Bossi P. Advanced CSCC Management in Immunotherapy Era: Achievements and New Challenges. Dermatol Pract Concept. 2023;13(4):e2023251. Go to original source... Go to PubMed...
- Neil DG, David MM, Nikhil IK, et al. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. N Eng J Med. 2022;387:17.